Alnylam: 4Q Earnings Snapshot

February 7, 2019

CAMBRIDGE, Mass. (AP) _ Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $211.4 million in its fourth quarter.

The Cambridge, Massachusetts-based company said it had a loss of $2.09 per share. Losses, adjusted for stock option expense, came to $1.82 per share.

The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of $1.97 per share.

The RNA interference drug developer posted revenue of $21 million in the period, which also beat Street forecasts. Five analysts surveyed by Zacks expected $12.5 million.

For the year, the company reported that its loss widened to $761.5 million, or $7.57 per share. Revenue was reported as $74.9 million.

Alnylam shares have climbed 11 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $80.80, a drop of 34 percent in the last 12 months.


This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ALNY at https://www.zacks.com/ap/ALNY

Update hourly